MGNX vs ZYME
MGNX: Clinical-stage biopharmaceutical company developing innovative antibody-based cancer therapeutics using proprietary DART, TRIDENT, and ADC platforms. ZYME: A clinical-stage biotechnology firm building value through a portfolio of novel multifunctional biotherapeutics and strategic royalty assets.
Side-by-side fundamentals
| Metric | MGNX | ZYME | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $4.10 | $28.67 | |
| Market cap as of 2026-08-24 | $261M | $2.0B | |
| Net margin as of 2026-08-24 | -44.8% | -126.3% | MGNX higher |
| Gross margin as of 2026-08-24 | +74.5% | n/a | |
| Operating margin as of 2026-08-24 | -40.5% | -140.3% | MGNX higher |
| ROE as of 2026-08-24 | -147.8% | -37.8% | ZYME higher |
| ROA as of 2026-08-24 | -28.4% | -25.2% | ZYME higher |
| Debt / equity as of 2026-08-24 | 3.24 | 1.51 | ZYME lower |
| Revenue growth (YoY) as of 2026-08-24 | +2.0% | +3.3% | ZYME higher |
| Revenue CAGR (3y) SEC XBRL | -0.5% | -36.4% | MGNX higher |
| Beta as of 2026-08-24 | 1.19 | 1.15 | |
| 1-year return as of 2026-08-21 close | +184.7% | +99.2% | MGNX higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.